On September 9, 2026, Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review of Cohort 1 of the Phase 1b registrational study for SER-252 in advanced Parkinson's disease and recommended advancing to Cohort 2. The cohort evaluated the lowest dose level in the single-ascending-dose portion, involving eight patients randomized 3:1 to receive SER-252 or placebo. Blinded observations indicated a pharmacokinetic profile consistent with sustained apomorphine exposure and sustained periods of improvement in motor function on exploratory clinical measures. The company expects to report topline data from the single-ascending-dose portion in the first half of 2027. Serina Therapeutics is a clinical-stage biotechnology company developing proprietary drug optimization technology for Parkinson's disease.

Serina Therapeutics reported financial results for the quarter ended June 30, 2026, reporting a net loss of $8.9 million, or $(0.55) per share, compared to a $6.6 million loss in the prior year period. Operating expenses increased to $6.8 million from $5.7 million, driven by higher R&D and G&A costs. The company completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational study for SER-252 ahead of schedule, with top-line data targeted for the first half of 2027. Cash and cash equivalents rose to $23.0 million as of June 30, 2026. The company also appointed Farrell Simon to its Board of Directors. Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates using its proprietary POZ Platform technology for neurological diseases.

Serina Therapeutics, Inc. entered into an Amended and Restated Employment Agreement with CEO Steve Ledger on July 19, 2026. Under the new terms, Mr. Ledger will receive an annual base salary of $500,000 and a target annual bonus of 50% of his base salary. The agreement outlines specific severance packages for termination without cause or resignation for good reason, including enhanced payouts and accelerated equity vesting in the event of a Change in Control. The contract also includes two-year non-competition and 18-month non-solicitation covenants. Serina Therapeutics is a biotechnology company focused on developing therapeutic solutions.

Serina Therapeutics, Inc. appointed Farrell Simon, Pharm. D., to its Board of Directors effective July 22, 2026. Dr. Simon, currently the Chief Commercial Officer at Trevi Therapeutics, Inc., will also serve as a member of the company's Audit and Compensation Committees. He brings expertise in commercial strategy, business development, and investor engagement, having previously held senior leadership roles at Pfizer. Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases using its proprietary POZ Platform™ technology.

On June 17, 2026, Serina Therapeutics, Inc. filed a certificate of amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock from 40,000,000 to 125,000,000. At its 2026 Annual Meeting, stockholders also approved increasing the 2024 Equity Incentive Plan by 2,000,000 shares, the conversion of certain Series A Preferred Stock into common stock, and the exercise of certain Private Placement Securities into common stock. The company operates in the biotechnology industry and develops therapeutic products.